



LKT Laboratories, Inc.

ASTX660

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID A744789

CAS No. 1799328-86-1

Chemical Name Ethanone, 1-(6-((4-fluorophenyl)methyl)-2,3-dihydro-5-(hydroxymethyl)-3,3-dimethyl-1H-pyrrolo(3,2-b)pyridin-1-yl)-2-((2R,5R)-5-methyl-2-(((3R)-3-methyl-4-morpholinyl)methyl)-1-

Synonym ASTX660, ASTX-660, ASTX 660

Formula C₃₀H₄₂FN₅O₃

Formula Wt. 539.70

Melting Point


Purity ≥98%

Solubility

Store Temp -20° C

Ship Temp Ambient

Description ASTX660 is an inhibitor of apoptosis proteins found to target BIR3 domain of cIAP1/2 and XIAP through a TNFalpha dependent mechanism in melanoma, breast cancer, and lymphoma cell studies. In a breast cancer xenograft model ASTX660 inhibited tumor growth while displaying no significant adverse effects. Treatment of squamous cell carcinoma xenograft models with combination of ASTX660 and radiotherapy showed synergistic effect of delayed tumor growth.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size
A744789	1 mg
A744789	5 mg
A744789	25 mg

References Ward G, Lewis E, Ahn J, et al. ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNFalpha-dependent apoptosis in cancer cell lines and inhibits tumor growth. *Mol Cancer Ther.* 2018 Jul;17(7):1381-1391. PMID: 29695633.

Xiao R, An Y, Ye W, et al. Dual antagonist of cIAP/XIAP ASTX660 sensitizes HPV- and HPV+ head and neck cancers to TNFalpha, TRAIL, and radiation therapy. *Clin Cancer Res.* 2019 Nov 1;25(21):6463-6474. PMID: 31266830.

Ye W, Gunti S, Allen C, et al. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. *Oncoimmunology.* 2020 Jan 9;9(1):1710398. PMID: 32002309.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.